文献速递慢性肾脏病

ASCEND-NHQ随机试验发现达格罗司他对非透析慢性肾脏病患者的血红蛋白和生活质量有积极影响

The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease.
PubMed 文献 · Kidney Int · 2023-03-02

ASCEND-NHQ多中心随机双盲安慰剂对照试验纳入614例非透析慢性肾脏病3-5期患者,口服达格罗司他或安慰剂28周。达格罗司他组血红蛋白自基线的校正均值变化为1.58 g/dl,安慰剂组为0.19 g/dl,校正均值治疗差异为1.40 g/dl(95%CI 1.23, 1.56);SF-36活力评分分别增加7.3分和1.9分,第28周校正均值治疗差异为5.4分;不良事件发生率相似(69% vs 71%)。

要点

  • 达格罗司他组血红蛋白自基线的校正均值变化为1.58 g/dl,安慰剂组为0.19 g/dl。
  • 达格罗司他组血红蛋白升高1 g/dl及以上的参与者比例为77%,安慰剂组为18%。
  • 第28周SF-36活力评分校正均值治疗差异为5.4分,达格罗司他组增加7.3分,安慰剂组增加1.9分。

核心结论

  • 在慢性肾脏病3-5期参与者中,达格罗司他导致血红蛋白显著升高和疲劳改善,且总体不良事件频率未增加。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照试验。
  • 纳入614例非透析依赖性慢性肾脏病3-5期成人,血红蛋白8.5-10.0 g/dl,转铁蛋白饱和度15%或以上,铁蛋白50 ng/ml或以上,且近期未使用红细胞生成刺激剂。
  • 按1:1随机分配至口服达格罗司他或安慰剂,目标是在28周内达到并维持血红蛋白11-12 g/dl。

主要发现

  • 主要终点:达格罗司他组血红蛋白自基线至评估期(第24-28周)的校正均值变化为1.58 g/dl,安慰剂组为0.19 g/dl;校正均值治疗差异为1.40 g/dl(95%CI 1.23, 1.56),达格罗司他组大于安慰剂组。
  • 次要终点:达格罗司他组血红蛋白自基线升高1 g/dl及以上的参与者比例为77%,安慰剂组为18%,达格罗司他组显著更高。
  • 次要终点:第28周SF-36活力评分校正均值治疗差异为5.4分,达格罗司他组增加7.3分,安慰剂组增加1.9分,达格罗司他组大于安慰剂组。
  • 不良事件发生率:达格罗司他组69%,安慰剂组71%;相对风险0.98(95%CI 0.88, 1.09)。

关键数值与推荐

  • 主要终点优效性检验采用单侧α水平0.025。
  • 血红蛋白目标为11-12 g/dl,持续28周。
  • 主要终点评估期为第24-28周。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The ASCEND-NHQ trial evaluated the effects of daprodustat on hemoglobin and the Medical Outcomes Study 36-item Short Form Survey (SF-36) Vitality score (fatigue) in a multicenter, randomized, double-blind, placebo-controlled trial. Adults with chronic kidney disease (CKD) stages 3-5, hemoglobin 8.5-10.0 g/dl, transferrin saturation 15% or more, and ferritin 50 ng/ml or more without recent erythropoiesis-stimulating agent use were randomized (1:1) to oral daprodustat or placebo to achieve and maintain target hemoglobin of 11-12 g/dl over 28 weeks. The primary endpoint was the mean change in hemoglobin between baseline and the evaluation period (Weeks 24-28). Principal secondary endpoints were proportion of participants with a 1 g/dl or more increase in hemoglobin and mean change in the Vitality score between baseline and Week 28. Outcome superiority was tested (1-sided alpha level of 0.025). Overall, 614 participants with non-dialysis-dependent CKD were randomized. The adjusted mean change in hemoglobin from baseline to the evaluation period was greater with daprodustat (1.58 vs 0.19 g/dl). The adjusted mean treatment difference (AMD) was significant at 1.40 g/dl (95% confidence interval 1.23, 1.56). A significantly greater proportion of participants receiving daprodustat showed a 1 g/dl or greater increase in hemoglobin from baseline (77% vs 18%). The mean SF-36 Vitality score increased by 7.3 and 1.9 points with daprodustat and placebo, respectively; a clinically and statistically significant 5.4 point Week 28 AMD increase. Adverse event rates were similar (69% vs 71%); relative risk 0.98, (95% confidence interval 0.88, 1.09). Thus, in participants with CKD stages 3-5, daprodustat resulted in a significant increase in hemoglobin and improvement in fatigue without an increase in the overall frequency of adverse events.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Johansen KL, Cobitz AR, Singh AK, et al. The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease. Kidney Int. 2023. PMID: 36868377. doi:10.1016/j.kint.2023.02.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。